StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a report published on Wednesday morning. The brokerage issued a sell rating on the stock. A number of other research analysts also recently commented on the company. Maxim Group dropped their price objective on Moleculin Biotech from $45.00 to $20.00 and set […]

Related Keywords

Roth Mkm , Atticus Wealth Management , Moleculin Biotech Inc , Maxim Group , Nasdaq , Moleculin Biotech , Free Report , Wealth Management , Get Free Report , Moleculin Biotech Daily ,